JPMorgan and Evercore ISI are acting as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
- Enanta announces $50M common stock offering
- Promising Phase 2b Trial Results for Enanta Pharmaceuticals’ Zelicapavir Boost Buy Rating and $20 Price Target
- Enanta Pharmaceuticals Announces Positive Phase 2b Results
- Enanta Pharmaceuticals Announces Positive Phase 2b RSV Study Results
- Enanta reports ‘positive’ results from Phase 2b study of zelicapavir